Episodes (Page 4)
✨
Neogene Therapeutics discusses TCR therapies for solid tumors.
✨
Ray Therapeutics uses optogenetics to restore vision.
✨
Tessera Therapeutics introduces Gene Writing technology.
Michael Severino
✨
Allogene Therapeutics discusses allogeneic therapy for CLL.
Zachary Roberts
✨
Dark Horse Consulting provides CGT regulatory update.
Kimberly Benton
✨
CureDuchenne discusses FDA approval for ELEVIDYS and gene therapy development for DMD.
Debra Miller
Michael Kelly
✨
Mammoth Biosciences explores ultracompact CRISPR systems for curative therapies.
Lucas Harrington
✨
KSQ Therapeutics discusses Tumor-Infiltrating Lymphocytes (TILs) for solid tumors.
Micah Benson
✨
Strand Therapeutics discusses programmable mRNA for precise protein expression.
Jake Becraft
✨
Elixirgen Therapeutics details their Bobcat mRNA therapy for DMD.
Aki Ko
✨
ISCT's Dr. Bambi Grilley discusses the global regulatory landscape for cell and gene therapies.
Bambi Grilley
✨
Dr. Bruce Levine previews ISCT 2024 and discusses CAR-T therapy's future.
✨
Dr. Marcus Conant on CGTs for HIV suppression.
✨
Dr. Ahmed Enayetallah on Parkinson's trial.
Ahmed Enayetallah
✨
Vor Bio's eHSC candidate shows clinical proof of concept in 8 patients.
Robert Ang
✨
Orca Bio discusses reducing toxicities in allogeneic cell therapies.
✨
Life Biosciences develops cellular rejuvenation therapies for age-related diseases.
Sharon Rosenzweig-Lipson
✨
The Jackson Laboratory discusses rare disease research and its mission.
Cat Lutz
✨
Kite Pharma reduced median turnaround time for Yescarta.
Christopher McDonald
✨
The Dedham Group analyzes pricing, value, and access for CGTs.
Jennifer Klarer